GGrantIndex
← Leaderboards

Lloyd C Trotman

State University New York Stony Brook

$10,047,682
Attributed
$12,533,642
Total exposure
9
Grants
8
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.

Funding over time

peak $1.7M · FY201025
$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25

Funding mix

By agency

NIH$12,533,642 · 9

By mechanism

R01$9,118,602 · 3
P30$2,992,554 · 5
T32$422,486 · 1

Top collaborators

Most similar at State University New York Stony Brook

Same institution · by research overlap

Others in their field

Top investigators on “Molecular

Research focus

MolecularNeoplasm MetastasisSamplingIn VivoTumorMalignant Neoplasm Of ProstateSignal TransductionProstateMetastatic Prostate CancerMalignant NeoplasmsCellsAnimalsProgramsFundingGenetically Engineered MouseTechnologyPositioning AttributeBaseResistanceMouse ModelIn VitroResponseCancer BiologyEvent

Grant awards (31)

Metastasis of PTEN Mutant Prostate Cancer$1,105,348
R01 · FY2025 · CA · contact PI
Animal & Tissue Imaging Shared Resource$455,147
P30 · FY2025 · CA · contact PI
Cancer Research Training and Education Coordination$85,121
P30 · FY2025 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$629,362
R01 · FY2024 · CA
Metastasis of PTEN Mutant Prostate Cancer$525,040
R01 · FY2024 · CA · contact PI
Animal & Tissue Imaging Shared Resource$444,876
P30 · FY2024 · CA · contact PI
Cancer Research Training and Education Coordination$93,354
P30 · FY2024 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$654,000
R01 · FY2023 · CA
Metastasis of PTEN Mutant Prostate Cancer$541,620
R01 · FY2023 · CA · contact PI
Animal & Tissue Imaging Shared Resource$455,147
P30 · FY2023 · CA · contact PI
Cancer Research Training and Education Coordination$85,121
P30 · FY2023 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$658,627
R01 · FY2022 · CA
Metastasis of PTEN Mutant Prostate Cancer$529,446
R01 · FY2022 · CA · contact PI
Animal & Tissue Imaging Shared Resource$455,147
P30 · FY2022 · CA · contact PI
Cancer Research Training and Education Coordination$85,121
P30 · FY2022 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$676,650
R01 · FY2021 · CA
Animal & Tissue Imaging Shared Resource$455,147
P30 · FY2021 · CA · contact PI
Cancer Research Training and Education Coordination$85,121
P30 · FY2021 · CA · contact PI
Development of the Next Generation of FABP5 Inhibitors to Treat Prostate Cancer$695,974
R01 · FY2020 · CA
Animal and Tissue Imaging Shared Resource$293,252
P30 · FY2020 · CA · contact PI
CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program$214,339
T32 · FY2020 · CA · contact PI
CSHL Cancer Gene Discovery and Cancer Biology Postdoctoral Research Training Program$208,147
T32 · FY2019 · CA · contact PI
Mechanism and treatment of PTEN mutant prostate tumorigenesis$398,400
R01 · FY2018 · CA · contact PI
Mechanism and treatment of PTEN mutant prostate tumorigenesis$398,400
R01 · FY2017 · CA · contact PI
Mechanism and treatment of PTEN mutant prostate tumorigenesis$398,400
R01 · FY2016 · CA · contact PI
Mechanism and treatment of PTEN mutant prostate tumorigenesis$398,400
R01 · FY2015 · CA · contact PI
Mechanism and treatment of PTEN mutant prostate tumorigenesis$392,175
R01 · FY2014 · CA · contact PI
Mechanisms and Treatment of PTEN Mutant Prostate Tumorigenesis$286,069
R01 · FY2013 · CA · contact PI
Mechanisms and Treatment of PTEN Mutant Prostate Tumorigenesis$301,376
R01 · FY2012 · CA · contact PI
Mechanisms and Treatment of PTEN Mutant Prostate Tumorigenesis$240,475
R01 · FY2011 · CA · contact PI
Mechanisms and Treatment of PTEN Mutant Prostate Tumorigenesis$288,840
R01 · FY2010 · CA · contact PI